<DOC>
	<DOCNO>NCT01967615</DOCNO>
	<brief_summary>Prasugrel ticagrelor associate significant reduction risk MACE patient undergo PCI ACS , mostly reduce stent thrombosis . The 1-year relative risk reduction ( RRR ) definite probable stent thrombosis patient receive DES fairly different TRITON-TIMI 38 PLATO trial . The incidence `` biologically active '' stent ( DES BVS ) thrombosis largely variable accord different lesion setting . We aim verify translation postulate different reduction thrombosis rate among various P2Y12 inhibitor ( clopidogrel , prasugrel ticagrelor ) high-risk set PCI DES BVS CTO bifurcate lesion .</brief_summary>
	<brief_title>P2Y12 Inhibitors Utilization Bifurcation Chronic Total Occlusion PCI</brief_title>
	<detailed_description>All patient age 18-80 underwent PCI CTO bifurcate lesion ( Medina type , side branch ≥2 mm ) `` biologically active stent '' ( DES BVS ) January 2012 december 2014 participate center deem eligible enter registry . In-hospital outcome record ; patient discharge alive follow telephone interview ( minimum follow-up 6 month ) . The primary end-point occurrence cluster major adverse cardiovascular event 1 year : 1 . Death cause . 2 . Myocardial infarction . 3 . Stent thrombosis , define definite , probable possible follow Academic Research Consortium . Sample size 3150 patient .</detailed_description>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>Age 1880 year old PCI CTO bifurcate lesion ( Medina type , side branch ≥2 mm ) `` biologically active stent ''</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>PCI ,</keyword>
	<keyword>CTO ,</keyword>
	<keyword>bifurcation ,</keyword>
	<keyword>clopidogrel ,</keyword>
	<keyword>prasugrel ,</keyword>
	<keyword>ticagrelor</keyword>
</DOC>